Oral contraceptives for pain associated with endometriosis

Endometriosis

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial

Fertil Steril.

Donnez J, Taylor HS, Taylor RN, Akin MD, Tatarchuk TF, Wilk K, Gotteland JP, Lecomte V, Bestel E

doi: 10.1016/j.fertnstert.

Endometriosis

Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study

Hum Reprod.

D'Hooghe T, Fukaya T, Osuga Y, Besuyen R, López B, Holtkamp GM, Miyazaki K, Skillern L

doi: 10.1093/humrep/dez028.

HPV and Gynecologic CancerReproductive Health

Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study

Am J Obstet Gynecol.

Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC

doi: 10.1016/j.ajog.2017.02.002.

Endometriosis

Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis

Fertil Steril.

Surrey ES, Soliman AM, Agarwal SK, Snabes MC, Diamond MP

doi: 10.1016/j.fertnstert.

Endometriosis

Clinically Meaningful Reduction in Dyspareunia Is Associated With Significant Improvements in Health-Related Quality of Life Among Women With Moderate to Severe Pain Associated With Endometriosis: A Pooled Analysis of Two Phase III Trials of Elagolix

J Sex Med.

Agarwal SK, Soliman AM, Pokrzywinski RM, Snabes MC, Coyne KS

doi: 10.1016/j.jsxm.2020.08.002.

Endometriosis

Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: Analysis of 2 phase III clinical trials

Am J Obstet Gynecol.

Pokrzywinski RM, Soliman AM, Chen J, Snabes MC, Coyne KS, Surrey ES, Taylor HS

doi: 10.1016/j.ajog.2019.11.1255.

Endometriosis

Optimal Management of Endometriosis and Pain

Obstet Gynecol.

Nezhat C, Vang N, Tanaka PP, Nezhat C

doi: 10.1097/AOG.

Endometriosis

Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials

Fertil Steril.

Pokrzywinski RM, Soliman AM, Chen J, Snabes M, Diamond MP, Surrey E, Coyne KS

doi: 10.1016/j.fertnstert.

COMMENTED

Endometriosis

Reduced pain thresholds and signs of sensitization in women with persistent pelvic pain and suspected endometriosis

Acta Obstet Gynecol Scand.

Grundström H, Gerdle B, Alehagen S, Berterö C, Arendt-Nielsen L, Kjølhede P

doi: 10.1111/aogs.13508.

Related content

Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial

Efficacy and safety of ASP1707 for endometriosis-associated pelvic pain: the phase II randomized controlled TERRA study

Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study

Impact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis

Clinically Meaningful Reduction in Dyspareunia Is Associated With Significant Improvements in Health-Related Quality of Life Among Women With Moderate to Severe Pain Associated With Endometriosis: A Pooled Analysis of Two Phase III Trials of Elagolix

Achieving clinically meaningful response in endometriosis pain symptoms is associated with improvements in health-related quality of life and work productivity: Analysis of 2 phase III clinical trials

Optimal Management of Endometriosis and Pain

Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials

Reduced pain thresholds and signs of sensitization in women with persistent pelvic pain and suspected endometriosis